Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions |
6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Contingencies And Commitments [Line Items] | ||||
| Defer option specified cost | $ 110.3 | $ 110.3 | ||
| Deferred Finance Costs, Share Lending Arrangement, Issuance Costs | 80.9 | $ 36.1 | ||
| Scenario Forecast [Member] | ||||
| Contingencies And Commitments [Line Items] | ||||
| Defer option specified cost | $ 110.3 | |||
| Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | ||||
| Contingencies And Commitments [Line Items] | ||||
| Milestone payment receivable | $ 200.0 | |||
| Cost excluded from license agreement | $ 4.0 | |||
| Letter of Credit [Member] | ||||
| Contingencies And Commitments [Line Items] | ||||
| Letters of credit secured by cash held in restricted depository account | 11.5 | |||
| 2015 Collaboration Agreement [Member] | Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | ||||
| Contingencies And Commitments [Line Items] | ||||
| Milestone payment receivable | $ 395.0 | |||